|Bid||105.26 x 800|
|Ask||106.00 x 1800|
|Day's Range||103.96 - 105.92|
|52 Week Range||73.69 - 105.92|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.21%)|
|1y Target Est||N/A|
Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.
INDIANAPOLIS, Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of common stock. The offering is expected to represent an ownership stake of less than 20 percent in Elanco. The company expects to complete the IPO process before the end of 2018.
INDIANAPOLIS, Aug. 1, 2018 /PRNewswire/ -- The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in the U.S. and all U.S. territories. Beginning today, this suite of solutions will provide many options – some being offered for the first time – that can significantly lower and cap high monthly out-of-pocket costs for some people who use Lilly insulins such as Humalog® (insulin lispro) and Humulin® (insulin human injection). "We don't want anyone to have to pay full list price for their insulin, and many people who do will be able to pay significantly less by calling our helpline," said Mike Mason, senior vice president, Connected Care and Insulins.
INDIANAPOLIS, July 30, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to help advance cancer care.
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU ...
Stock Research Monitor: LLY, MRK, and NVS LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . On Wednesday, benchmark US ...
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...
- Second-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined. - Second-quarter 2018 earnings per share ...
INDIANAPOLIS, July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission (SEC) for a potential initial public offering (IPO) of a minority ownership stake in Elanco as a separate company. The offering is expected to represent an ownership stake of less than 20 percent. The company expects to complete the IPO process during the second half of 2018.
INDIANAPOLIS , July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented ...
INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 ...
RIDGEFIELD, Conn. and INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Tradjenta® demonstrating similar cardiovascular safety compared with placebo. Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with placebo on cardiovascular safety on top of standard of care. The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- The U.S. label for Eli Lilly and Company's (LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD). The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin.1 Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist (RA) injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes.
Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients.
LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY) ("Eli Lilly"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On June 28, 2018, the Company declared that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, which is a Phase-3 study evaluating Taltz® for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Eli Lilly.
INDIANAPOLIS, June 29, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today initiation of the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) study, which aims to be the largest study of its kind in the field of migraine, engaging 40,000 people with migraine throughout the U.S. during the next two years. The objectives of the study are to further understand the burden of migraine and the stigma experienced by people living with migraine, identify barriers to the use of preventive and acute treatments for migraine and to assess how the introduction of novel preventive and acute treatment options may influence delivery of migraine care and costs of care in real-world settings.
INDIANAPOLIS , June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018 . Lilly will also conduct a conference ...
INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). This is the first AS study focusing on a difficult-to-treat population of patients who had an inadequate response to one or two tumor necrosis factor (TNF) inhibitors (90 percent of enrolled patients) or intolerance to a TNF inhibitor (10 percent). Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS, as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40 (ASAS40) response at 16 weeks, when compared to placebo.
INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™ (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with BOTOX®* (onabotulinumtoxinA). Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented as a late-breaking presentation on Saturday, June 30 at the American Headache Society (AHS) annual meeting in San Francisco. Emgality is a once-monthly, self-administered calcitonin gene-related peptide (CGRP) antibody currently under review by the FDA for the prevention of migraine in adults.
Detailed primary and secondary results will be presented Saturday, June 30 as a late-breaking presentation at the American Headache Society (AHS) annual meeting in San Francisco. In this study, patients with episodic cluster headache treated with Emgality (300 mg once-monthly) experienced statistically significant differences in the reduction of weekly cluster headache attacks compared to patients treated with placebo across Weeks 1 to 3 of the two-month, double-blind treatment period (-8.7 for Emgality compared to -5.2 for placebo, p=0.036), the primary endpoint of the study.
INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company's (LLY) Humulin® R U-500 administered via an investigational insulin pump (Omnipod® U-500™ Insulin Management System) provided greater A1C reduction with less daily insulin needed compared to multiple daily injections (MDI) in adults with type 2 diabetes on high dose insulin (201-600 units/day).1 Data from this phase 3 study will be presented for the first time today in an oral session at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando. Humulin R U-500 is Lilly's highly concentrated insulin formulation that is used to control high blood sugar in people with diabetes who are insulin-resistant and need daily doses of more than 200 units of insulin.
RIDGEFIELD, Conn. and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in A1C after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10 and 25 mg). Type 1 diabetes currently affects 1.3 million adults in the U.S. and approximately 30 million adults worldwide.
INDIANAPOLIS , June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for ...
INDIANAPOLIS, June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity® (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data.1,2 These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions® in Orlando. Trulicity is Eli Lilly and Company's (LLY) once-weekly, injectable GLP-1 RA approved to improve blood sugar (glucose) in adults with type 2 diabetes. Trulicity is available in 0.75 mg and 1.5 mg and should be used along with diet and exercise.